Carlyle Group Inc. (NASDAQ:CG) is a global investment firm known for its diverse portfolio and strategic investments. On February 6, 2026, CG reported its earnings, revealing an earnings per share (EPS) of $1.01, slightly below the estimated $1.03. Despite this, the company generated a revenue of approximately $1.09 billion, surpassing the estimated $1.07 billion.
The company's fourth-quarter results were impressive, as highlighted by Bloomberg, with fee-related earnings growing by 12% for the year, reaching a record $1.2 billion. This achievement doubled the firm's original goal, showcasing the company's strong performance. Fourth-quarter distributable earnings increased by 14% from the previous year, amounting to $436 million.
Fundraising played a crucial role in Carlyle's success, with the firm raising $53.7 billion in fresh capital during 2025. This was bolstered by its credit and AlpInvest platforms. Carlyle deployed $54.5 billion over the same period and generated $34 billion from asset sales, including the initial public offering of Medline.
Carlyle's financial metrics provide further insight into its market position. The company has a price-to-earnings (P/E) ratio of approximately 31.96, indicating investor confidence. Its price-to-sales ratio stands at about 5.73, reflecting the market's valuation of its revenue. However, the enterprise value to operating cash flow ratio is negative at -12.56, suggesting challenges in cash flow generation.
The company's debt-to-equity ratio is 2.25, highlighting its financial leverage. This ratio indicates the proportion of debt used to finance its assets, which is a key consideration for investors. Despite these challenges, Carlyle's earnings yield of approximately 3.13% provides insight into the return on investment for shareholders.
